Kiniksa Pharmaceuticals International (KNSA) EBIT (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported EBIT for 10 consecutive years, with $27.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 34.89% year-over-year to $27.2 million; the trailing twelve-month figure through Jun 2026 stood at $100.2 million (up 2140.22% YoY), and the FY2025 full-year result was $77.2 million, up 269.28% from the prior year.
• EBIT slipped to $27.2 million in Q2 2026 per KNSA's latest filing, from $29.3 million in the prior quarter.
• Across five years, EBIT topped out at $46.4 million in Q3 2022 and bottomed at -$23.3 million in Q1 2022.
• Historically, EBIT has averaged $4.0 million across 5 years, with a median of -$18000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: EBIT sank 23925.93% in 2024, then soared 17330.77% in 2025.
• Over 5 years, EBIT stood at $6.0 million in 2022, then slumped by 98.66% to $81000.0 in 2023, then tumbled by 23925.93% to -$19.3 million in 2024, then soared by 202.43% to $19.8 million in 2025, then jumped by 37.57% to $27.2 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered $27.2 million, $29.3 million, and $19.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.